Biohaven (BHVN) to Release Earnings on Monday

Biohaven (NYSE:BHVN) will likely be announcing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($1.22) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Biohaven Trading Down 1.4%

Shares of BHVN opened at $11.23 on Monday. Biohaven has a twelve month low of $7.48 and a twelve month high of $40.82. The stock has a market cap of $1.19 billion, a PE ratio of -1.48 and a beta of 1.14. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 1.91. The business’s 50-day moving average price is $11.52 and its 200-day moving average price is $12.84.

Hedge Funds Weigh In On Biohaven

Several institutional investors and hedge funds have recently made changes to their positions in BHVN. E Fund Management Co. Ltd. boosted its stake in shares of Biohaven by 20.6% during the second quarter. E Fund Management Co. Ltd. now owns 13,492 shares of the company’s stock valued at $190,000 after purchasing an additional 2,307 shares during the period. PDT Partners LLC purchased a new position in shares of Biohaven in the second quarter worth $392,000. Raymond James Financial Inc. raised its holdings in Biohaven by 40.8% during the 2nd quarter. Raymond James Financial Inc. now owns 32,614 shares of the company’s stock valued at $460,000 after buying an additional 9,443 shares during the last quarter. Osaic Holdings Inc. boosted its position in Biohaven by 150.5% during the 2nd quarter. Osaic Holdings Inc. now owns 9,791 shares of the company’s stock valued at $147,000 after buying an additional 5,883 shares during the period. Finally, Twinbeech Capital LP purchased a new stake in Biohaven during the 4th quarter valued at $132,000. Institutional investors own 88.78% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on BHVN shares. TD Cowen reaffirmed a “buy” rating on shares of Biohaven in a report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Biohaven in a research report on Monday, December 29th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Biohaven in a report on Wednesday, November 5th. Robert W. Baird set a $42.00 price objective on Biohaven in a research note on Wednesday, November 5th. Finally, Sanford C. Bernstein restated a “market perform” rating and issued a $9.00 target price (down from $34.00) on shares of Biohaven in a research note on Thursday, November 6th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Biohaven has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.